Rephonic
Artwork for The BioCentury Show

The BioCentury Show

BioCentury
FDA
Biotechnology
Clinical Trials
Drug Pricing
Drug Development
Biotech
China
Biologics
Pharmaceutical Industry
Gene Therapy
Biosimilars
Inflation Reduction Act
Artificial Intelligence
Cancer Treatments
Novartis
Oncology
Mergers and Acquisitions
Immunology
Drug Regulation
Obesity

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine.

Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues.

The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how scien... more

PublishesTwice monthlyEpisodes64Founded2 years ago
Number of ListenersCategories
ScienceLife SciencesBusiness

Listen to this Podcast

Artwork for The BioCentury Show

Latest Episodes

Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with E... more

YouTube

ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discus... more

YouTube

Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing that millions of patients have b... more

YouTube

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”

In a wide-ranging interview on The BioCentury Show with BioCentury Was... more

YouTube

Key Facts

Accepts Guests
Accepts Sponsors
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Biotech Hangout
Biotech HangoutDaphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler and more

Recent Guests

Karen Knudsen
CEO of the Parker Institute for Cancer Immunotherapy
Parker Institute for Cancer Immunotherapy
Episode: Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
Chris Hollowood
CEO of Syncona Investment Management Limited
Syncona Investment Management Limited
Episode: Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy
Sander Slootweg
Co-founder and managing partner, Forbion
Forbion
Episode: Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
Daniel Mahony
Senior partner in growth investments at Novo Holdings; former chair of the BIA (UK)
Novo Holdings
Episode: Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
Najat Khan
CEO and President
Recursion Pharmaceuticals
Episode: Ep. 105 - Recursion’s Najat Khan: AI Will Be Judged by the Medicines It Delivers
Jacqueline Fok
Investment Director focused on Life Sciences & Health Tech at SoftBank Vision Fund
SoftBank Vision Fund
Episode: Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
Naoki Okamura
President and CEO of Astellas Pharma
Astellas Pharma
Episode: Ep. 101 - Why Science Stalls: Astellas CEO Naoki Okamura on Translation, Talent and Platforms
Adam Koppel
Partner at Bain Capital Life Sciences, with extensive experience in private equity and biopharmaceutical investments
Bain Capital Life Sciences
Episode: Ep. 100 - Adam Koppel on Why Private Equity Is Moving Deeper Into Biotech and What Comes Next
Stelios Papadopoulos
A prominent biotech executive known for his leadership roles in companies like Exelixis and Biogen.
Exelixis
Episode: Ep. 99 – Stelios Papadopoulos on Biotech’s Long View: Pricing Pressure, China & Big Pharma

Hosts

Steve Usdin
BioCentury's Washington editor and host, overseeing discussions on policy, regulation, and industry dynamics.
Simone Fishburn
Editor-in-Chief guiding conversations with top scientists and industry leaders.
Selina Koch
Executive Editor providing leadership, framing discussions with guests.

Reviews

4.7 out of 5 stars from 23 ratings
  • Wow

    Insightful and full of great info every time! Thx!

    Apple Podcasts
    5
    Surfrider182
    United States2 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Content is data-driven and heavily focused on translating science into practical outcomes for patients and markets.
Guests are typically senior decision-makers with a strong track record in biotech or policy.
Peers consistently note the show delivers actionable, industry-relevant insights.
Sponsorships and partner messages are integrated but stay complementary to expert discussions.

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development
Q: Where do you see China fitting into the global ecosystem for developing therapies for cancer?
China is increasingly a source for first-in-human studies and a way to lower discovery and translation costs, and the global system should leverage that while maintaining collaboration and information sharing.
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
Q: How does Forbion view sourcing assets from Asia and what has changed in late-stage asset availability?
The approach leverages a two-angle strategy: high-quality assets from Asia with local partners and the ability to develop them for Western markets, plus strong KOL input and late-stage clinical paths. While late-stage assets were once highly available, they've become more scarce, prompting a shift toward slightly earlier-stage opportunities and more intensive collaboration with Asian partners to keep a global pipeline.
Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing
Q: What has driven Forbion's rapid growth and what is the current geographic split of their investments?
Forbion's growth stems from scaling fund sizes to match an expanding opportunity set across Europe and the US, with a strategic pivot to a growth fund and a more global footprint, including a Boston office, while maintaining a strong Europe core. Venture investments are roughly 60-65% Europe and 35-40% US/Canada, with growth nearing 50-50 between Europe and North America.
Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform
Q: How does AI influence biotech strategy and operations for smaller companies?
AI can level the playing field by accelerating literature review, due diligence, and regulatory document generation, as well as enabling real-time sequencing improvements, which together can reduce operating costs and lengthen funding runway for small companies.
Ep. 104 - SoftBank’s Jacqueline Fok on AI Drug Development, Metsera and the U.K. Biotech Opportunity
Q: What should we watch for in the coming year in this space?
Key catalysts include updates on GLP-1 combination data from Metsera and Pfizer, innovations in biotech business models (e.g., model licensing and funding strategies), and continued progress from portfolio companies such as Encoded Therapeutics, Umoja Therapeutics, and Ventus Therapeutics.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About The BioCentury Show

What is The BioCentury Show about and what kind of topics does it cover?

This program delivers in-depth conversations with senior leaders across biotech, pharma, investment, and policy, focusing on how science translates into real-world medicines. Recent episodes span translational science and patient access, AI-driven drug discovery, European and UK biotech capital markets, regulatory and pricing policy, and strategies for de-risking discovery and accelerating clinical progress. Guests include top executives, investors, and policymakers who share practical insights on building companies, funding approaches, and navigating global regulatory landscapes. The show distinguishes itself with data-rich discussions, cross-border perspectives, and a clear emphasis on turning scientific advances into accessible therapies... more

Where can I find podcast stats for The BioCentury Show?

Rephonic provides a wide range of podcast stats for The BioCentury Show. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to The BioCentury Show and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does The BioCentury Show get?

Rephonic provides a full set of podcast information for three million podcasts, including the number of listeners. View further listenership figures for The BioCentury Show, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for The BioCentury Show?

Rephonic provides comprehensive predictive audience data for The BioCentury Show, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does The BioCentury Show have?

To see how many followers or subscribers The BioCentury Show has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to The BioCentury Show?

These podcasts share a similar audience with The BioCentury Show:

1. BioCentury This Week
2. Biotech Hangout
3. The Readout Loud
4. The Long Run with Luke Timmerman
5. Biotech 2050 Podcast

How many episodes of The BioCentury Show are there?

The BioCentury Show launched 2 years ago and published 64 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact The BioCentury Show?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for The BioCentury Show?

Rephonic pulls ratings and reviews for The BioCentury Show from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for The BioCentury Show?

Rephonic provides full transcripts for episodes of The BioCentury Show. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on The BioCentury Show?

Recent guests on The BioCentury Show include:

1. Karen Knudsen
2. Chris Hollowood
3. Sander Slootweg
4. Daniel Mahony
5. Najat Khan
6. Jacqueline Fok
7. Naoki Okamura
8. Adam Koppel

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days